# A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Source: https://onco.cc/trials/nct02138734/  
OnCo record `nct02138734` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BCG (50mg/instillation) + N-803 (400 μg/instillation) in bladder & urothelial cancer, run by ImmunityBio, Inc., active and no longer recruiting.

## Summary

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT02138734 by ImmunityBio, Inc., with 369 participants enrolled, started 2014-07-21 and due to reach its primary completion in 2026-09-30. Interventions recorded: BCG (50mg/instillation) + N-803 (400 μg/instillation) and BCG (50mg/instillation).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02138734
- Phase: 1/2
- Setting: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
- Sponsor: ImmunityBio, Inc.
- Enrolled: 369

## Sources

- ClinicalTrials.gov NCT02138734: https://clinicaltrials.gov/study/NCT02138734

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct02138734.json